TipRanks
Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
US Market
GOSS
Gossamer Bio
RESEARCH TOOLSreports
Want to see GOSS full AI Analyst Report?

Gossamer Bio (GOSS) Stock Forecast & Price Target

1,460 Followers
See the Price Targets and Ratings of:

GOSS Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
3 Buy
2 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Gossamer
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GOSS Stock 12 Month Forecast

Average Price Target

$86.48
▲(43140.00% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Gossamer Bio in the last 3 months. The average price target is $86.48 with a high forecast of $160.00 and a low forecast of $22.40. The average price target represents a 43140.00% change from the last price of $0.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","252":"$252","69.75":"$69.8","130.5":"$130.5","191.25":"$191.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$160.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$86.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,69.75,130.5,191.25,252],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.93,22.396923076923077,33.863846153846154,45.33076923076923,56.79769230769231,68.26461538461538,79.73153846153846,91.19846153846154,102.66538461538462,114.1323076923077,125.59923076923079,137.06615384615384,148.53307692307692,{"y":160,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.93,16.74153846153846,22.553076923076922,28.364615384615387,34.17615384615385,39.98769230769231,45.799230769230775,51.610769230769236,57.4223076923077,63.23384615384616,69.04538461538462,74.85692307692308,80.66846153846154,{"y":86.48,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.93,11.812307692307693,12.694615384615384,13.576923076923077,14.459230769230768,15.34153846153846,16.223846153846154,17.106153846153845,17.988461538461536,18.87076923076923,19.75307692307692,20.635384615384616,21.517692307692307,{"y":22.4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":199.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.288,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.584,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.848,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.415,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.559,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.392,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.93,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$160.00Average Price Target$86.48Lowest Price Target$22.40
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Chardan Capital Analyst forecast on GOSS
Andreas Argyrides
Chardan Capital
Chardan Capital
$160
Buy
79900.00%
Upside
Initiated
10/13/26
Gossamer Bio initiated with a Buy at ChardanGossamer Bio initiated with a Buy at Chardan
Guggenheim Analyst forecast on GOSS
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
09/23/26
Guggenheim Sticks to Their Hold Rating for Gossamer Bio (GOSS)
H.C. Wainwright Analyst forecast on GOSS
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$90
Buy
44900.00%
Upside
Reiterated
09/21/26
Gossamer Bio target adjusted to $90 for split at H.C. WainwrightGossamer Bio target adjusted to $90 for split at H.C. Wainwright
Wedbush Analyst forecast on GOSS
Laura Chico
Wedbush
Wedbush
$80
Hold
39900.00%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (NASDAQ: GOSS), Nektar Therapeutics (NASDAQ: NKTR) and Aprea Therapeutics (NASDAQ: APRE)
Barclays Analyst forecast on GOSS
Eliana Merle
Barclays
Barclays
$22.4
Sell
11100.00%
Upside
Reiterated
07/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Gossamer Bio (NASDAQ: GOSS)
Leerink Partners Analyst forecast on GOSS
Joseph Schwartz
Leerink Partners
Leerink Partners
$80
Buy
39900.00%
Upside
Upgraded
07/27/26
Gossamer Bio upgraded to Outperform from Market Perform at LeerinkGossamer Bio upgraded to Outperform from Market Perform at Leerink
Cantor Fitzgerald Analyst forecast on GOSS
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
03/20/26
Gossamer Bio downgraded to Neutral from Overweight at Cantor FitzgeraldGossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
Piper Sandler Analyst forecast on GOSS
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$1,200
Buy
599900.00%
Upside
Reiterated
03/18/26
Analysts Are Bullish on Top Healthcare Stocks: Gossamer Bio (GOSS), Alto Neuroscience, Inc. (ANRO)
Goldman Sachs Analyst forecast on GOSS
Paul Choi
Goldman Sachs
Goldman Sachs
$640→$40
Hold
19900.00%
Upside
Downgraded
02/24/26
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (NASDAQ: GOSS) and PepGen Inc. (NASDAQ: PEPG)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Chardan Capital Analyst forecast on GOSS
Andreas Argyrides
Chardan Capital
Chardan Capital
$160
Buy
79900.00%
Upside
Initiated
10/13/26
Gossamer Bio initiated with a Buy at ChardanGossamer Bio initiated with a Buy at Chardan
Guggenheim Analyst forecast on GOSS
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
09/23/26
Guggenheim Sticks to Their Hold Rating for Gossamer Bio (GOSS)
H.C. Wainwright Analyst forecast on GOSS
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$90
Buy
44900.00%
Upside
Reiterated
09/21/26
Gossamer Bio target adjusted to $90 for split at H.C. WainwrightGossamer Bio target adjusted to $90 for split at H.C. Wainwright
Wedbush Analyst forecast on GOSS
Laura Chico
Wedbush
Wedbush
$80
Hold
39900.00%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (NASDAQ: GOSS), Nektar Therapeutics (NASDAQ: NKTR) and Aprea Therapeutics (NASDAQ: APRE)
Barclays Analyst forecast on GOSS
Eliana Merle
Barclays
Barclays
$22.4
Sell
11100.00%
Upside
Reiterated
07/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Gossamer Bio (NASDAQ: GOSS)
Leerink Partners Analyst forecast on GOSS
Joseph Schwartz
Leerink Partners
Leerink Partners
$80
Buy
39900.00%
Upside
Upgraded
07/27/26
Gossamer Bio upgraded to Outperform from Market Perform at LeerinkGossamer Bio upgraded to Outperform from Market Perform at Leerink
Cantor Fitzgerald Analyst forecast on GOSS
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
03/20/26
Gossamer Bio downgraded to Neutral from Overweight at Cantor FitzgeraldGossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
Piper Sandler Analyst forecast on GOSS
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$1,200
Buy
599900.00%
Upside
Reiterated
03/18/26
Analysts Are Bullish on Top Healthcare Stocks: Gossamer Bio (GOSS), Alto Neuroscience, Inc. (ANRO)
Goldman Sachs Analyst forecast on GOSS
Paul Choi
Goldman Sachs
Goldman Sachs
$640→$40
Hold
19900.00%
Upside
Downgraded
02/24/26
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (NASDAQ: GOSS) and PepGen Inc. (NASDAQ: PEPG)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
SIBNSI-Bone
IMUXImmunic
MDWDMediwound
HROWHarrow Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gossamer Bio

3 Months
Joseph SchwartzLeerink Partners
Success Rate
10/16 ratings generated profit
63%
Average Return
+21.83%
Copying Joseph Schwartz's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +21.83% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
7/16 ratings generated profit
44%
Average Return
+17.50%
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +17.50% per trade.
2 Years
Andreas ArgyridesChardan Capital
Success Rate
6/16 ratings generated profit
38%
Average Return
-5.37%
Copying Andreas Argyrides's trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -5.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GOSS Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
3
5
5
4
3
Buy
0
0
0
0
0
Hold
3
4
3
4
3
Sell
2
2
1
1
0
Strong Sell
0
0
0
0
0
total
8
11
9
9
6
In the current month, GOSS has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. GOSS average Analyst price target in the past 3 months is 86.48.
Each month's total comprises the sum of three months' worth of ratings.

GOSS Financial Forecast

GOSS Earnings Forecast

Next quarter’s earnings estimate for GOSS is -$3.79 with a range of -$7.23 to $0.80. The previous quarter’s EPS was -$6.40. GOSS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GOSS has Performed in-line its overall industry.
Next quarter’s earnings estimate for GOSS is -$3.79 with a range of -$7.23 to $0.80. The previous quarter’s EPS was -$6.40. GOSS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GOSS has Performed in-line its overall industry.

GOSS Sales Forecast

Next quarter’s sales forecast for GOSS is $12.16M with a range of $0.00 to $40.93M. The previous quarter’s sales results were $9.24M. GOSS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GOSS has Performed in-line its overall industry.
Next quarter’s sales forecast for GOSS is $12.16M with a range of $0.00 to $40.93M. The previous quarter’s sales results were $9.24M. GOSS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GOSS has Performed in-line its overall industry.

GOSS Stock Forecast FAQ

What is GOSS’s average 12-month price target, according to analysts?
Based on analyst ratings, Gossamer Bio Inc’s 12-month average price target is 86.48.
    What is GOSS’s upside potential, based on the analysts’ average price target?
    Gossamer Bio Inc has 43140.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GOSS a Buy, Sell or Hold?
          Gossamer Bio Inc has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Gossamer Bio Inc’s price target?
            The average price target for Gossamer Bio Inc is 86.48. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $160.00 ,the lowest forecast is $22.40. The average price target represents 43140.00% Increase from the current price of $0.2.
              What do analysts say about Gossamer Bio Inc?
              Gossamer Bio Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of GOSS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.